Company Filing History:
Years Active: 2023
Title: Kathleen Ogilvie: Innovator in Lung Inflammation Therapies
Introduction
Kathleen Ogilvie is a prominent inventor based in San Diego, CA, who has made significant contributions to the field of medical therapies. She is particularly known for her work in developing treatments for lung inflammation, which is a critical area of research given the increasing prevalence of interstitial lung diseases (ILDs).
Latest Patents
Kathleen holds 1 patent for her innovative work titled "Compositions and methods for treating lung inflammation." This patent provides therapies, including combination therapies, for the treatment of lung inflammation, specifically targeting interstitial lung diseases. The invention includes the use of at least one histidyl-tRNA synthetase (HRS) polypeptide or an expressible polynucleotide that encodes the HRS polypeptide, either alone or in combination with at least one immunomodulatory agent.
Career Highlights
Kathleen has established herself as a key figure in the biotechnology sector, particularly through her role at Atyr Pharma, Inc. Her research and development efforts have focused on creating effective therapies that address complex medical conditions, showcasing her commitment to improving patient outcomes.
Collaborations
One of her notable collaborators is John D. Mendlein, with whom she has worked closely to advance their shared goals in medical innovation. Their partnership exemplifies the collaborative spirit that drives progress in the field of biotechnology.
Conclusion
Kathleen Ogilvie's contributions to the treatment of lung inflammation highlight her role as an influential inventor in the medical field. Her innovative approaches and dedication to research continue to pave the way for advancements in therapies for interstitial lung diseases.